Bryan Johnson wants $1M per year to share his longevity secrets. The criticism is already pouring in

Bryan Johnson, the fintech founder who has spent the past five years turning himself into the world’s most visible anti-ageing experiment, announced on 12 February that he is selling access to his personal longevity protocol for $1 million per year. The programme, called “Immortals,” is limited to three participants. According to Johnson, applications are already flooding in.

The backlash has been equally swift.

What the programme promises

In a post on X, Johnson described Immortals as “the world’s best health program,” claiming it replicates “the exact protocol I have followed for the last 5 years.” The package includes a dedicated concierge team, continuous biological tracking across “millions of data points,” what Johnson calls “best skin and hair protocols,” access to cutting-edge therapies, and round-the-clock availability of “BryanAI” — an AI system modelled on Johnson himself.

The promise, stripped to its essence, is that three individuals wealthy enough to pay the fee will receive a personalised version of the regime Johnson has publicly documented under the brand name “Blueprint” — a programme that has included hundreds of supplements, strict dietary protocols, rigorous exercise routines, and an array of experimental medical interventions.

Johnson, 48, made his fortune selling his payments company Braintree to eBay for $800 million in 2013. He has since invested what he says is more than $2 million annually into his own body, turning his biological data into content that has attracted millions of followers across social media platforms.

A business model built on aspiration — and exclusivity

The $1 million price tag positions Immortals at the extreme apex of a booming longevity market. The global anti-ageing industry was valued at approximately $67 billion in 2023 and is projected to exceed $120 billion by 2030, according to estimates from Grand View Research. Johnson is not the first to monetise longevity science for the ultra-wealthy — clinics in Switzerland, Singapore, and the United States already offer bespoke health optimisation programmes costing six figures — but few have done so with such theatrical flair.

The scarcity framing is deliberate. By limiting enrolment to three spots, Johnson deploys a classic luxury-market tactic: artificial constraint amplifying perceived value. The message is not merely that the programme is expensive but that it is rare, that most people — regardless of their means — will be turned away.

For those who cannot afford the seven-figure entry fee, Johnson’s commercial ecosystem offers lower-priced alternatives. His supplement line and branded olive oil — described by TechCrunch as “peppery and smooth” — serve as accessible on-ramps to the Johnson brand. The Immortals programme, in this context, functions less as a standalone revenue stream than as a marketing pinnacle: the aspirational peak that lends credibility and glamour to everything sold below it.

The criticism: science, ethics, and spectacle

The most pointed critiques of Immortals centre not on the price but on the evidence — or lack thereof — underpinning Johnson’s claims.

Johnson has never published his anti-ageing protocol in a peer-reviewed journal. His biological age measurements, which he says show meaningful reversal of ageing markers, rely on epigenetic clocks and biomarker panels whose predictive validity remains a subject of active scientific debate. Epigenetic age tests, while increasingly sophisticated, are not universally accepted as reliable proxies for biological ageing, and their results can be influenced by short-term lifestyle changes that may not correspond to genuine lifespan extension.

As Newser reported, the programme has attracted significant criticism alongside its applicants. Johnson’s prior interventions — including receiving blood plasma transfusions from his teenage son, a procedure he later abandoned, and publicly experimenting with psilocybin — have drawn scepticism from mainstream medical professionals who question whether such practices are grounded in rigorous science or amount to expensive self-experimentation broadcast as content.

TechCrunch’s coverage struck a notably sardonic tone, observing that Johnson — born in 1977, “a year in which many current humans were born” — has not yet demonstrated any capacity to outlive his peers. The publication also drew a pointed comparison to other tech-industry figures making grandiose claims, noting the pattern of Silicon Valley luminaries asking the public to trust their judgment on matters far outside their original expertise.

The structural dynamic: longevity as luxury good

The deeper significance of Immortals lies in what it reveals about the evolving relationship between wealth, health, and technology.

For most of human history, the gap between rich and poor manifested in material possessions — land, housing, goods. Over the past two decades, that gap has increasingly expressed itself in health outcomes. Wealthier individuals in OECD countries already live, on average, significantly longer than their lower-income counterparts — a disparity driven by access to better nutrition, preventive care, lower stress, and cleaner environments.

Programmes like Immortals threaten to accelerate this divergence. If even a fraction of the interventions Johnson promotes prove effective, their initial availability will be restricted to those who can pay. The ethical question is not whether wealthy people should be permitted to spend their money on health — they always have — but whether the emerging longevity industry is creating a two-tier system in which biological ageing itself becomes a marker of socioeconomic class.

This concern is not hypothetical. Peter Attia, a physician and longevity researcher whose book Outlive became a bestseller in 2023, has argued that the most impactful longevity interventions — exercise, sleep optimisation, metabolic health management — are largely accessible and inexpensive. The risk, Attia and others have noted, is that flashy, high-cost programmes distort public understanding of what actually extends life, redirecting attention and resources toward unproven interventions while basic public health measures remain underfunded.

The role of AI in Johnson’s pitch

The inclusion of “BryanAI” — an AI assistant available to Immortals clients around the clock — introduces another layer of complexity. Johnson has not disclosed the technical architecture of the system, but the implication is that it draws on his accumulated biological data and protocol knowledge to provide personalised guidance.

This raises questions about liability, medical regulation, and the boundary between wellness coaching and healthcare. In most jurisdictions, providing personalised health recommendations based on biological data falls under medical practice regulations. Whether BryanAI constitutes medical advice, and who bears responsibility if a client is harmed following its guidance, are questions that neither Johnson nor his team have publicly addressed.

The AI component also reflects a broader trend in the wellness industry: the use of technology to scale personal brands beyond what any individual could deliver alone. If BryanAI can approximate Johnson’s decision-making, the logical next step is to offer it at lower price points to a wider audience — a move that would transform Johnson from a longevity practitioner into a longevity platform.

What the market signals suggest

That Johnson reportedly has numerous applicants for just three spots suggests that demand among the ultra-wealthy for personalised, concierge-level health optimisation is robust — a finding consistent with the rapid growth of executive health clinics and precision medicine startups in both the United States and Europe.

The European longevity sector, while less flamboyant than its American counterpart, has seen substantial investment in recent years. Companies across the continent are building platforms for biological age testing, personalised nutrition, and AI-driven health coaching — often with a more evidence-based posture than the influencer-driven model Johnson represents.

The tension between scientific rigour and commercial ambition is not new to the health industry, but the longevity space amplifies it. The stakes — life and death, or at least the promise of more life — make consumers unusually susceptible to aspirational marketing. And the absence of regulatory frameworks specifically designed for longevity interventions means that the market is, for now, largely self-policing.

Johnson’s Immortals programme will not, in itself, determine the trajectory of the longevity industry. But it crystallises the forces shaping it: the monetisation of biological data, the blurring of wellness and medicine, the deployment of AI as a proxy for expertise, and the widening gap between those who can afford to optimise their biology and those who cannot. The question facing regulators, scientists, and the public is whether this emerging market will be governed by evidence or by spectacle. At $1 million a year, the early returns favour spectacle.